Pharmaceuticals
NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance
Now commercially available, the medium cut-off dialyzer expands access to enhanced middle molecule removal through existing dialysis infrastructure OSAKA, Japan and BRIDGEWATER, N.J., Aug. 4, 2026 /PRNewswire/ -- NIPRO CORPORATION, through its U.S.-based subsidiary Nipro Medical Corporation, toda...
2026-08-04 22:01
2678
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS
2026-08-04 18:15
2462
Sisram Medical Powers Up China EBD Growth Engine with Flagship "黑金牛奶光" Launch
Driving Innovation and Proactive Empowerment to Unlock Localized Growth in China HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today un...
2026-08-04 17:37
4447
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to improve cancer care. KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRN...
2026-08-04 06:00
15445
Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
PUNE, India, Aug. 4, 2026 /PRNewswire/ -- Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), today announced the launch of NeX™, a transformative end-to-end partnership model that enables governments, institutions, and biopharma organizations to ...
2026-08-04 02:25
4334
KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System
BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Orthopaedic and Rheumatology Centre of Excellence ("CoE") at KPJ Penang Specialist Hospital ("KPJ Penang"), marking the third CoE under the KPJ Health System ("K...
2026-08-04 00:06
4456
Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in non-human primates announced for first-in-class once-da...
2026-08-03 18:55
3694
Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026)
KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "D...
2026-07-30 22:15
3226
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food ...
2026-07-30 20:10
2325
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings mor...
2026-07-30 20:00
1646
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan...
2026-07-30 17:19
2570
Fosun International Issues Positive Profit Alert: Profit Attributable to Owners of the Parent for 1H2026 Expected to be Approx. RMB 1.5 Billion to RMB1.8 Billion
HONG KONG, July 29, 2026 /PRNewswire/ -- On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of app...
2026-07-29 17:35
4254
AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer
* ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have received one to three prior s...
2026-07-29 10:00
2701
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-28 18:44
1728
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Fi...
2026-07-27 23:17
3194
Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
* STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases * Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information * Seegene to v...
2026-07-27 21:00
7065
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,today reaffirmed its strategic focus on pursuing global li...
2026-07-27 20:20
3279
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
* Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volum...
2026-07-27 20:10
3683
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...
2026-07-27 19:40
3815
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA...
2026-07-27 18:42
4297
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 279 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 274 media titles]
2026-09-25 14:45
